Medical Drug Benefit Clinical Criteria Updates

Total Page：16

File Type：pdf, Size：1020Kb

UniCare Health Plan of West Virginia, Inc. Medicaid Managed Care Provider Bulletin August 2020 Medical drug benefit Clinical Criteria updates On February 21, 2020, May 15, 2020, and June 18, 2020, the Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for UniCare Health Plan of West Virginia, Inc. These policies were developed, revised or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: New: newly published criteria Revised: addition or removal of medical necessity requirements, new document number Annual review: minor wording and formatting updates, new document number Updates marked with an asterisk (*): criteria may be perceived as more restrictive Please share this notice with other members of your practice and office staff. Please note: The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical plan. This does not apply to pharmacy services. Effective date Document number Clinical Criteria title New, revised, annual review 10/20/2020 ING-CC-0164* Jelmyto (mitomycin gel) New 10/20/2020 ING-CC-0165* Trodelvy (sacituzumab govitecan) New 10/20/2020 ING-CC-0029 Dupixent (dupilumab) Revised 10/20/2020 ING-CC-0107 Bevacizumab for Non-Ophthalmologic Indications Revised 10/20/2020 Darzalex (daratumumab) and Darzalex Faspro ING-CC-0127* Revised (daratumumab and hyaluronidase-fihj) 10/20/2020 ING-CC-0128 Tecentriq (atezolizumab) Revised 10/20/2020 ING-CC-0125 Opdivo (nivolumab) Revised 10/20/2020 ING-CC-0119 Yervoy (ipilimumab) Revised 10/20/2020 Enzyme Replacement Therapy for Gaucher ING-CC-0051* Revised Disease 10/20/2020 GnRH Analogs for the Treatment of Non- ING-CC-0061* Revised Oncologic Indications 10/20/2020 ING-CC-0042 Monoclonal Antibodies to Interleukin-17 Revised 10/20/2020 ING-CC-0011* Ocrevus (ocrelizumab) Revised 10/20/2020 ING-CC-0002* Colony Stimulating Factor Agents Revised www.unicare.com UniCare Health Plan of West Virginia, Inc. UWVPEC-1645-20 August 2020 .

Copy Link

Recommended publications

Ocrevus (Ocrelizumab) Policy Number: C11250-A
Prior Authorization Criteria Ocrevus (ocrelizumab) Policy Number: C11250-A CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE LAST REVIEWED DATE NEXT REVIEW DUE BY OR BEFORE 8/1/2017 2/17/2021 4/26/2022 LAST P&T J CODE TYPE OF CRITERIA APPROVAL/VERSION J2350-injection,ocrelizumab, Q2 2021 RxPA 1mg 20200428C11250-A PRODUCTS AFFECTED: Ocrevus (ocrelizumab) DRUG CLASS: Multiple Sclerosis Agents - Monoclonal Antibodies ROUTE OF ADMINISTRATION: Intravenous PLACE OF SERVICE: Specialty Pharmacy or Buy and Bill The recommendation is that medications in this policy will be for pharmacy benefit coverage and the IV infusion products administered in a place of service that is a non-hospital facility-based location (i.e., home infusion provider, provider’s office, free-standing ambulatory infusion center) AVAILABLE DOSAGE FORMS: Ocrevus SOLN 300MG/10ML FDA-APPROVED USES: Indicated for the treatment of: • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease, in adults • Primary progressive MS, in adults COMPENDIAL APPROVED OFF-LABELED USES: None COVERAGE CRITERIA: INITIAL AUTHORIZATION DIAGNOSIS: Multiple Sclerosis REQUIRED MEDICAL INFORMATION: A. RELAPSING FORMS OF MULTIPLE SCLEROSIS: 1. Documentation of a definitive diagnosis of a relapsing form of multiple sclerosis as defined by the McDonald criteria (see Appendix), including: Relapsing- remitting multiple sclerosis [RRMS], secondary-progressive multiple sclerosis [SPMS] with relapses, and progressive- relapsing multiple sclerosis [PRMS] or First clinical episode with MRI features consistent with multiple sclerosis Molina Healthcare, Inc. confidential and proprietary © 2021 This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare.
[Show full text]
ADC Therapeutics SA (Exact Name of Registrant As Specified in Its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2020. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ADC Therapeutics SA Date: July 6, 2020 By: /s/ Dominique Graz Name: Dominique Graz Title: General Counsel EXHIBIT INDEX Exhibit No. Description 99.1 Press release dated July 6, 2020 Exhibit 99.1 ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine Lausanne, Switzerland — July 6, 2020 — ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology, today announced that the U.S.
[Show full text]
Comparative Effectiveness of Pembrolizumab Vs. Nivolumab In
www.nature.com/scientificreports OPEN Comparative efectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC Pengfei Cui1,2,4, Ruixin Li2,4, Ziwei Huang3,2,4, Zhaozhen Wu3,2, Haitao Tao2, Sujie Zhang2 & Yi Hu1,2,3* The efcacies of pembrolizumab and nivolumab have never been directly compared in a real-world study. Therefore, we sought to retrospectively evaluate the objective response rate (ORR) and the progression-free survival (PFS) of patients with recurrent or advanced non-small cell lung cancer (NSCLC) in a real-world setting. This study included patients with recurrent or advanced NSCLC diagnosed between September 1, 2015 and August 31, 2019, who were treated with programmed cell death 1 (PD-1) inhibitors at the Cancer Center of the Chinese People’s Liberation Army. PFS was estimated for each treatment group using Kaplan–Meier curves and log-rank tests. The multivariate analysis of PFS was performed with Cox proportional hazards regression models. A total of 255 patients with advanced or recurrent NSCLC treated with PD-1 inhibitors were identifed. The ORR was signifcantly higher in the pembrolizumab group than in the nivolumab group, while PFS was not signifcantly diferent between the two groups. Subgroup analysis showed that the ORR was signifcantly higher for pembrolizumab than for nivolumab in patients in the frst-line therapy subgroup and in those in the combination therapy as frst-line therapy subgroup. Survival analysis of patients receiving combination therapy as second- or further-line therapy showed that nivolumab had better efcacy than pembrolizumab. However, the multivariate analysis revealed no signifcant diference in PFS between patients treated with pembrolizumab and those treated with nivolumab regardless of the subgroup.
[Show full text]
Cutaneous Adverse Effects of Biologic Medications
REVIEW CME MOC Selena R. Pasadyn, BA Daniel Knabel, MD Anthony P. Fernandez, MD, PhD Christine B. Warren, MD, MS Cleveland Clinic Lerner College Department of Pathology Co-Medical Director of Continuing Medical Education; Department of Dermatology, Cleveland Clinic; of Medicine of Case Western and Department of Dermatology, W.D. Steck Chair of Clinical Dermatology; Director of Clinical Assistant Professor, Cleveland Clinic Reserve University, Cleveland, OH Cleveland Clinic Medical and Inpatient Dermatology; Departments of Lerner College of Medicine of Case Western Dermatology and Pathology, Cleveland Clinic; Assistant Reserve University, Cleveland, OH Clinical Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH Cutaneous adverse effects of biologic medications ABSTRACT iologic therapy encompasses an expo- B nentially expanding arena of medicine. Biologic therapies have become widely used but often As the name implies, biologic therapies are de- cause cutaneous adverse effects. The authors discuss the rived from living organisms and consist largely cutaneous adverse effects of tumor necrosis factor (TNF) of proteins, sugars, and nucleic acids. A clas- alpha inhibitors, epidermal growth factor receptor (EGFR) sic example of an early biologic medication is inhibitors, small-molecule tyrosine kinase inhibitors insulin. These therapies have revolutionized (TKIs), and cell surface-targeted monoclonal antibodies, medicine and offer targeted therapy for an including how to manage these reactions
[Show full text]
Chelsea & Westminster Healthcare Trust Drugs Committee
Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group Summary of Main Points from the Meeting held on Monday 12th December 2016 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the November 2016 Medicines Group meeting were approved and will be circulated. 3. Matters Arising The Group noted the matters arising from the previous meeting. 4. Business to be transacted by the Medicines Group 4.1 Formulary Applications Ex-panel Deferasirox (Exjade®) 90mg, 180mg and 360mg Tablets (Novartis) Exjade® film coated tablets have been introduced in November 2016. These will take the place of the dispersible tabs which will be phased out and no longer available from June 2017. Costs are equivalent to the dispersible tablets. The new film coated tablets have a number of advantages over the dispersible tablets including: - Can be swallowed whole - Lactose free - No food restrictions - No mixing/preparation required. Decision: Approved DuoResp Spiromax® 160 micrograms / 4.5 micrograms (Budesonide & Formoterol) Inhalation Powder (Teva) Request by the Respiratory Team for the management of asthma in line with the BTS guidelines where a ® combination of an inhaled long acting B2 agonist and corticosteroid is indicated. Adding DuoResp Spiromax to the formulary will provide an increased choice of devices available to prescribe. Symbicort Turbohaler® is already included on the formulary. DuoResp Spiromax® is more cost-effective than Symbicort Turbohaler® and is currently included on the NWLIF and GPs have already started to prescribe it. Decision: Approved Sodium Valpoate (Epilim Chronosphere®) 50mg and 100mg Modified Release Granules (Sanofi) Requested by the Paediatric Neurology Team for paediatric patients requiring sodium valpoate in very low doses.
[Show full text]
New Biological Therapies: Introduction to the Basis of the Risk of Infection
New biological therapies: introduction to the basis of the risk of infection Mario FERNÁNDEZ RUIZ, MD, PhD Unit of Infectious Diseases Hospital Universitario “12 de Octubre”, Madrid ESCMIDInstituto de Investigación eLibraryHospital “12 de Octubre” (i+12) © by author Transparency Declaration Over the last 24 months I have received honoraria for talks on behalf of • Astellas Pharma • Gillead Sciences • Roche • Sanofi • Qiagen Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Paul Ehrlich (1854-1915) • “side-chain” theory (1897) • receptor-ligand concept (1900) • “magic bullet” theory • foundation for specific chemotherapy (1906) • Nobel Prize in Physiology and Medicine (1908) (together with Metchnikoff) Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author 1981: B-1 antibody (tositumomab) anti-CD20 monoclonal antibody 1997: FDA approval of rituximab for the treatment of relapsed or refractory CD20-positive NHL 2001: FDA approval of imatinib for the treatment of chronic myelogenous leukemia Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Functional classification of targeted (biological) agents • Agents targeting soluble immune effector molecules • Agents targeting cell surface receptors
[Show full text]
Statistical Analysis Plan
Official Title: A Phase IIIb, Open-Label Study to Evaluate the Safety and Tolerability of Shorter Infusions of Ocrelizumab in Patients With Primary Progressive and Relapsing Multiple Sclerosis NCT Number: NCT03606460 Document Date: SAP Version 1: 26-June-2019 STATISTICAL ANALYSIS PLAN TITLE: A PHASE IIIB, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SHORTER INFUSIONS OF OCRELIZUMAB IN PATIENTS WITH PRIMARY PROGRESSIVE AND RELAPSING MULTIPLE SCLEROSIS PROTOCOL NUMBER: ML40638 STUDY DRUG: Ocrelizumab (RO4964913) VERSION NUMBER: 1 IND NUMBER: 100,593 EUDRACT NUMBER: Not applicable SPONSOR: Genentech, Inc. PLAN PREPARED BY: DATE FINAL: 26 June, 2019 STATISTICAL ANALYSIS PLAN APPROVAL Approved by Ph.D. on June 26, 2019 CONFIDENTIAL This is a Genentech, Inc. document that contains confidential information. Nothing herein is to be disclosed without written consent from Genentech, Inc. Ocrelizumab—Genentech, Inc. Statistical Analysis Plan ML40638 Clinical Study Report: Ocrelizumab — Genentech, Inc. CSR ML40638 370 TABLE OF CONTENTS 1. BACKGROUND ............................................................................................ 5 2. STUDY DESIGN ........................................................................................... 5 2.1 Protocol Synopsis .................................................................... 6 2.2 Outcome Measures ................................................................. 6 2.2.1 Primary Endpoint ..................................................................... 6 2.2.2 Secondary
[Show full text]
The Ocrelizumab Pharmacy Service at the Leeds Teaching Hospitals NHS Trust (LTHT): Improving the Patient Experience
The Ocrelizumab Pharmacy Service at the Leeds Teaching Hospitals NHS Trust (LTHT): Improving the Patient Experience Jeremy Robson & Sumrah Shaffiq, Leeds Teaching Hospitals NHS Trust Neurology Academy MS Advanced MasterClass 9.2 Background In 2018, the approval of Ocrevus (ocrelizumab) offered another treatment option for the management of relapsing remitting Multiple Sclerosis (RRMS)1, but the breakthrough decision came in 2019 upon its approval for early primary progressive MS (PPMS)2. The West Yorkshire MS Treatment Programme (WYMST) was set up to centralise a multi- district clinic and provides an effective model to ensure appropriate and equitable treatment for people with MS3. The WYMST has approximately 600 RRMS and approximately 100 PPMS from Leeds. Patients eligible for ocrelizumab are consented by the MS team and the prescribing is undertaken by independent pharmacist prescribers (IPPs). Ocrelizumab is administered on the LTHT day case unit, which is also used for the management of other neurology conditions. The IPPs contribute to the prescribing for these patients. Prescribing of ocrelizumab is undertaken on paper drug charts. At LTHT, the compounding of a majority of monoclonal antibodies (MAbs) (e.g. rituximab, alemtuzumab, infliximab, ocrelizumab) are overseen by the aseptics department. This is the default position to guarantee a sterile product and also mitigate the potential risk to staff members. This part of the service review involved challenging discussions between the IPPs, their aseptics colleagues and the MS team. The approval of ocrelizumab for RRMS and PPMS means a potential increase in prescribing, day case admissions and aseptics involvement in the manufacture of MAbs. A service review was warranted to establish if the current approach ensured the LTHT ocrelizumab service was efficient, safe and patient-centred.
[Show full text]
Attachment: Extract from Clinical Evaluation Ocrelizumab
AusPAR Attachment 2 Extract from the Clinical Evaluation Report for ocrelizumab Proprietary Product Name: Ocrevus Sponsor: Roche Products Pty Limited First round report: October 2016 Second round report: February 2017 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website < https://www.tga.gov.au>. About the Extract from the Clinical Evaluation Report · This document provides a more detailed evaluation of the clinical findings, extracted from the Clinical Evaluation Report (CER) prepared by the TGA. This extract does not include sections from the CER regarding product documentation or post market activities. · The words (Information redacted), where they appear in this document, indicate that confidential information has been deleted. · For the most recent Product Information (PI), please refer to the TGA website < https://www.tga.gov.au/product-information-pi>.
[Show full text]
Nivolumab in Metastatic Non–Small Cell Lung Cancer
PRESCRIBER'S CORNER Section Editors: Christopher J. Campen and Beth Eaby-Sandy Nivolumab in Metastatic Non–Small Cell Lung Cancer ANDREA DEEL, PharmD From Kingsport Hematology Oncology, ung cancer is the leading NSCLC has led to the development of Kingsport, Tennessee cause of cancer deaths in agents that target specific molecular Author’s disclosures of potential conflicts of interest are found at the end of this article. the United States (Ameri- pathways in cancer cells (Kerr et al., Correspondence to: Andrea Deel, PharmD, can Cancer Society [ACS], 2014). Targeted therapies are a signifi- Kingsport Hematology Oncology, 4485 West L2015). Non–small cell lung cancer cant step forward in treating patients Stone Drive, Suite 200, Kingsport TN 37660. (NSCLC) is one of the most common with tumors that contain specific mu- E-mail: [email protected] types of the disease and accounts tations in these pathways. doi: 10.6004/jadpro.2016.7.2.7 for 85% to 90% of lung cancer cases In the United States, several agents © 2016 Harborside Press® (ACS, 2015). Nonsquamous NSCLC have been approved to target these accounts for approximately 45% to tumors. They include erlotinib, afa- 60% of all lung cancer cases, where- tinib (Gilotrif ), and gefitinib (Iressa), as squamous NSCLC accounts for which target EGFR signaling; crizo- approximately 25% to 30% of all lung tinib (Xalkori) and ceritinib (Zykadia), cancer cases (ACS, 2015). which target ALK rearrangements; Survival rates vary depending on bevacizumab (Avastin) and ramuci- the stage and type of the cancer and rumab (Cyramza), which target vascu- when it is diagnosed. For stage IV lar endothelial growth factor (VEGF) NSCLC, the 5-year survival rate is 1% signaling.
[Show full text]
Antibody–Drug Conjugates: the Last Decade
pharmaceuticals Review Antibody–Drug Conjugates: The Last Decade Nicolas Joubert 1,* , Alain Beck 2 , Charles Dumontet 3,4 and Caroline Denevault-Sabourin 1 1 GICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France; [email protected] 2 Institut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien en Genevois, France; [email protected] 3 Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS 5286/UCBL, 69000 Lyon, France; [email protected] 4 Hospices Civils de Lyon, 69000 Lyon, France * Correspondence: [email protected] Received: 17 August 2020; Accepted: 10 September 2020; Published: 14 September 2020 Abstract: An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of. Keywords: antibody–drug conjugate; ADC; bioconjugation; linker; payload; cancer; resistance; combination therapies 1.
[Show full text]
Imatinib (Gleevec™)
Biologicals What Are They? When Did All of this Happen? There are Clear Benefits. Are there also Risks? Brian J Ward Research Institute of the McGill University Health Centre Global Health, Immunity & Infectious Diseases Grand Rounds – March 2016 Biologicals Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. National Cancer Institute (USA) What Effects Do Steroids Have on Immune Responses? This is your immune system on high dose steroids projects.accessatlanta.com • Suppress innate and adaptive responses • Shut down inflammatory responses in progress • Effects on neutrophils, macrophages & lymphocytes • Few problems because use typically short-term Virtually Every Cell and Pathway in Immune System ‘Target-able’ (Influenza Vaccination) Reed SG et al. Nature Medicine 2013 Nakaya HI et al. Nature Immunology 2011 Landscape - 2013 Antisense (30) Cell therapy (69) Gene Therapy (46) Monoclonal Antibodies (308) Recombinant Proteins (93) Vaccines (250) Other (81) http://www.phrma.org/sites/default/files/pdf/biologicsoverview2013.pdf Therapeutic Category Drugs versus Biologics Patented Ibuprofen (Advil™) Generic Ibuprofen BioSimilars/BioSuperiors ? www.drugbank.ca Patented Etanercept (Enbrel™) BioSimilar Etanercept Etacept™ (India) Biologics in Cancer Therapy Therapeutic Categories • Hormonal Therapy • Monoclonal antibodies • Cytokine therapy • Classical vaccine strategies • Adoptive T-cell or dendritic cells transfer • Oncolytic
[Show full text]